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Endogenous and synthetic agonists of GPR119
differ in signalling pathways and their effects
on insulin secretion in MIN6c4 insulinoma cells
Y Ning, K O’Neill, H Lan, L Pang, LX Shan, BE Hawes and JA Hedrick
Department of Cardiovascular and Metabolic Disease, Schering-Plough Research Institute, Kenilworth, NJ, USA
Background and purpose: GPR119 is a G protein-coupled receptor that is preferentially expressed in islet cells and mediates
insulin secretion. Oleoyl-lysophosphatidylcholine and oleoylethanolamide (OEA) act as endogenous ligands for this receptor,
whereas PSN375963 and PSN632408 are two recently reported synthetic agonists. In this study, we explored mechanisms
underlying GPR119-induced insulin secretion. In addition, we assessed the potential utility of the synthetic agonists as tools for
exploring GPR119 biology.
Experimental approach: We examined natural and synthetic GPR119 agonist activity at GPR119 in MIN6c4 and RINm5f
insulinoma cells. We evaluated insulin secretion, intracellular calcium ½Ca
2þ i, ion channel involvement and levels of cAMP.
Key results: We report that increases in insulin secretion induced by OEA were associated with increased cAMP and a
potentiation of glucose-stimulated increases in ½Ca
2þ i. We also demonstrate that ATP-sensitive K
þ and voltage-dependent
calcium channels were required for GPR119-mediated increases in glucose-stimulated insulin secretion. In contrast to OEA, the
synthetic GPR119 agonist PSN375963 and PSN632408 have divergent effects on insulin secretion, cAMP and intracellular
calcium in MIN6c4 cells.
Conclusions and implications: The endogenous ligand OEA signals through GPR119 in a manner similar to glucagon-like
peptide-1 (GLP-1) and its receptor with respect to insulin secretion, ½Ca
2þ iand cAMP. In addition, PSN375963 and
PSN632408 substantially differ from OEA and from one another. These studies suggest that the commercially available
synthetic agonists, although they do activate GPR119, may also activate GPR119-independent pathways and are thus
unsuitable as GPR119-specific pharmacological tools.
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Introduction
In the last decade, an increasing number of unliganded
G protein-coupled receptors, so-called orphan receptors,
with unknown function have been identified, and they
present new opportunities for drug discovery. GPR119 is
one such orphan receptor, first identified through bioinfor-
matics methods and cloned in 2003 (Fredriksson et al.,
2003). Although GPR119 clearly belongs to the family
of rhodopsin-like G protein-coupled receptors, it exhibits
little overall sequence homology to other receptors. Further
distinguishing features of this receptor are the localization of
its gene on the X-chromosome and its relatively narrow
expression pattern. GPR119 expression is restricted largely
to pancreatic islets, although lesser amounts of message
are detected in the human gastrointestinal tract and in the
rodent brain (Soga et al., 2005; Overton et al., 2006).
Recently, oleoyl-lysophosphatidylcholine (OLPC) and
oleoylethanolamide (OEA) were identified as endogenous
ligands for GPR119 (Soga et al., 2005; Overton et al., 2006).
OLPC was reported to bind to GPR119, causing increased
intracellular cAMP accumulation and an increase in glucose-
stimulated insulin secretion (GSIS) in NIT-1 insulinoma cells.
OEA, a lipid-signalling agent previously shown to be a ligand
for peroxisome proliferator-activated receptor (PPAR)-a that
suppresses food intake (Fu et al., 2003), is also reported to
be an endogenous ligand for GPR119 (Overton et al., 2006).
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www.brjpharmacol.orgThis report also revealed two synthetic GPR119 agonists,
PSN375963 and PSN632408, that increased intracellular
cAMP in a GPR119-dependent manner. Although the effects
of OEA or the synthetic agonists on insulin secretion were
not reported, Overton et al. (2006) showed that PSN632408
or OEA could suppress feeding to a similar extent. These
findings led the authors to suggest that suppression of
feeding by OEA might be mediated through GPR119. More
recently, Chu et al. (2007) reported a potent synthetic
agonist for GPR119-designated AR231453. They demon-
strated that this compound increased intracellular cAMP
and insulin secretion in a GPR119-dependent manner, but
did not explore other signalling events. Finally, AR231453
was shown to have in vivo effects, improving oral glucose
tolerance in wild-type, but not in GPR119 knockout mice.
The effects of AR231453 on feeding were not reported.
A growing body of evidence supports an important
function for GPR119 in regulating metabolic responses.
GPR119 appears similar to the glucagon-like peptide-1
receptor (GLP-1R) in that they are both Gs-coupled receptors
and activation of either receptor leads to an increase in GSIS
(Soga et al., 2005; Drucker, 2006). In addition, activation of
GPR119 in the intestine leads to increased GLP-1 and
glucose-dependent insulinotropic polypeptide secretion
(Chu et al., 2008). This makes GPR119 of particular interest,
as a drug target similar to small molecule agonists of GLP-1R
have so far not been identified. Compared with GLP-1R,
however, we still know relatively little about the function of
GPR119. In particular, the signalling events (beyond cAMP)
that lead to GPR119-mediated increases in GSIS have not
been explored.
Here, we have examined the endogenous ligand, OEA, and
provided further characterization of the GPR119 signalling
pathways leading to insulin secretion. In addition, we
provide some comparisons between GPR119 signalling and
the well-characterized signalling of GLP-1Rs. We show that
the endogenous GPR119 ligand, OEA, potentiates glucose-
stimulated increases in intracellular calcium ½Ca
2þ iand
cAMP in a manner similar to that of GLP-1, and that the
ATP-sensitive K
þ (KATP) and the voltage-dependent calcium
(VDC) channels involved in GLP-1R-mediated insulin secre-
tion are also required for GPR119-induced insulin release. In
contrast, two reported synthetic agonists PSN375963 and
PSN632408 appear to have divergent effects on ½Ca
2þ i, cAMP
and insulin secretion that distinguish them from the
endogenous GPR119 ligand OEA and would appear to make
them unsuitable as GPR119-specific research tools.
Materials and methods
Insulinoma cell culture
Mouse MIN6c4 insulinoma cells (a subclone of Min6 cells
selected for high insulin secretion) were licensed from
Professor Jun-ichi Miyazaki (Osaka University Medical
School, Osaka, Japan). MIN6c4 cells were cultured in
Dulbecco’s modified Eagle’s medium containing 15% (v/v)
heat-inactivated foetal bovine serum 4.5gL
 1 glucose, 50mM
2-mercaptoethanol, 100UmL
 1 penicillin. Cells were incu-
bated in a humidified atmosphere at 371C with 5% CO2.
Rat RINm5f insulinoma cells were maintained in RPMI
1640 medium containing 2mML -glutamine, 1.5gL
 1
sodium bicarbonate, 4.5gL
 1 glucose, 10mM HEPES,
1.0mM sodium pyruvate and 10% FBS. For cells stably
expressing human GPR119, RINm5f cells were transfected
with 5mg of human-GPR119 cDNA (pCDNA3.1) using
Nucleofector Solution V and an Amaxa Nucleofector II
(Amaxa Biosystems, Germany). Transfected cells were then
selected and maintained in culture media with 500mgmL
 1
geneticin. Stable clones were obtained by limiting dilution
and the expression of human-GPR119 in RINm5f cells was
confirmed by quantitative PCR using an ABI 7700 instru-
ment (Perkin-Elmer, Waltham, MA, USA). The clone expres-
sing the highest levels of human GPR119 mRNA was selected
from among ten candidates and used for the insulin
secretion assays.
Measurement of insulin release
Measurement of insulin release was carried out in HEPES–
Krebs–Ringer bicarbonate buffer (KRBH, containing CaCl2,
1.26mM; KCl, 5.4mM;K H 2PO4, 0.44mM; MgCl2 6H2O,
0.5mM; MgSO4 7H2O, 0.4mM; NaCl, 0.14 M; NaHCO3,
4.1mM;N a 2HPO4, 0.34mM; HEPES, 20mM; pH 7.0) without
BSA, which can bind to OEA and OLPC and decrease the free
concentration of ligand availability. MIN6c4 cells were
plated in 96-well plate (3 10
4 cells per well) for 3 days
(70–80% confluence). On the day of experiment, the cell
culture medium was aspirated and the plate was washed
twice with KRBH buffer. Cells were rested at 371C for 30min
in KRBH containing 2.8mM glucose. Compounds were
dissolved in either 2.8 or 16mM glucose and added to cells
for 2h before collecting supernatant for insulin measure-
ments. In some experiments, nitrendipine or diazoxide (in
KRBH) were added after the 30min rest period and incubated
for 10min before the addition of other compounds. Insulin
concentration in the supernatant was determined using a
mouse insulin assay kit from Meso Scale Diagnostics
(Gaithersburg, MD, USA). Data are expressed as percentage
of control with control concentrations noted in the figure
legends.
Calcium assays
MIN6c4 cells were seeded into poly-D-lysine-coated 384-well
plates at 8 10
3 cells per well and cultured at 371C for 2 or 3
days (90% confluence). On the day of experiment, cells were
loaded for 1h at 371C with 1mM BD dye (BD Biosciences,
Franklin Lakes, NJ, USA) in KRBH buffer solution containing
2.8mM glucose, 10mM HEPES, 1mM CaCl2, 1.25mM
probenecid. The plate was cooled to room temperature and
compounds were added. Changes in intracellular calcium
content were monitored for up to 20min using a Fluoro-
metric Imaging Plate Reader (FLIPR, Molecular Devices,
Sunnyvale, CA, USA) (Schroeder, 1996). Occasionally, minor
changes in calcium were observed after addition of either
vehicle or compound. These presumably resulted from
mechanical stimulation or displacement of cells following
pipetting by the FLIPR. Changes in calcium are only
discussed if they were reproducibly observed.
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MIN6c4 cells were seeded into poly-D-lysine-coated 96-well
plates at 30 10
3 cells per well and cultured at 371C for 2 or
3 days (90% confluence). On the day of experiments, cells
were incubated in KRBH (without BSA) with 2.8mM glucose
for 30min. Cells were subsequently brought to 2.8mM and
16mM glucose with the addition of the indicated concentra-
tions of forskolin, GLP-1, OEA, PSN632408 and PSN375963.
The cAMP levels were measured after 2h incubation by
cAMP EIA kits (Cayman Chemical Co., Ann Arbor, MI, USA),
then normalized to the protein concentration in each well.
Three replicates were measured for each treatment and data
are presented as percentage of the control release in 2.8mM
glucose or 16mM glucose (mean±s.e.mean).
Gene expression analysis
Total RNA from RINm5f, RINm5f-GPR119 and MIN6c4 were
extracted utilizing the Ultraspec RNA isolation kit (Biotecx,
Houston, TX, USA). cDNA was generated by reverse trans-
cription using random hexamers (Promega, Madison, WI,
USA) and oligo-dT primers (Invitrogen Life Technologies,
Carlsbad, CA, USA). Quantitative real-time reverse trans-
criptase PCR analysis (referred to as TaqMan) was performed
on an ABI 7700 sequence-detection instrument following
manufacturer’s instructions. For TaqMan analysis, 25ng of
cDNA was used together with primers at a final concentra-
tion of 0.9mM, and carboxyfluorescein labelled diagnostic
probe at a final concentration of 0.25mM. Ribosomal 18S
RNA primers and probe (PE Applied Biosystems, Foster City,
CA, USA) were used as an internal control. The sequences of
50-primer, 30-primer and the probe were as follows: Gpr119
(NM_181751): cttctactgtgacatgctcaagattg, ccatggctcctg-
catgttc, ccatggctcctgcatgttc; data were analysed using Se-
quence Detection Systems software Version 1.7.
Data analysis
Data are reported as mean±s.e.mean. For the assays of
insulin release, statistical analysis was performed using
one-way ANOVA, with Bonferroni post-tests. *Po0.05;
**Po0.01. Data from cAMP assays were compared using
Student’s t-test implemented in GraphPad Prism 4.0
(GraphPad Software Inc., La Jolla, CA, USA).
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Figure 1 GPR119 agonists increase insulin secretion in RIN cell
lines. (a and b) The RINm5f and RIN-119 cells were stimulated by
16mM glucose, with or without the presence of 30nM glucagon-like
peptide-1, 10mM oleoylethanolamide, 10mM oleoyl-lysophosphatidyl-
choline, 10mM PSN375963 and PSN632408 as indicated. The insulin
levels from the triplicates were measured for each treatment and data
were presented as ng insulin per ml (mean±s.e.mean). *Po0.05;
**Po0.01 using ANOVA-Bonferroni, compared with insulin induced
by 16mM glucose alone in the same cell line.
Table 1 cAMP levels in MIN6c4 cells treated with forskolin, GLP-1, OEA, PSN632408 and PSN375963 in presence of 2.8 and 16mM glucose
Treatment In the presence of 2.8mM glucose In the presence of 16mM glucose
Mean±s.e.mean (% of
2.8mM glucose control)
P-value
(vs 2.8mM glucose)
Mean±s.e.mean
(% of 16mM glucose control)
P-value
(vs 16mM glucose)
Forskolin (40mM) 980±116 0.002 1291±203 0.004
GLP-1 (50nM) 144±9 0.007 446±69 0.007
OEA (3.3mM)9 8 ±10 0.87 142±13 0.027
OEA (10mM) 104±5 0.5 121±6 0.026
PSN632408 (3.3mM)8 5 ±7 0.1 161±17 0.02
PSN632408 (10mM) 112±19 0.56 141±5 0.001
PSN375963 (3.3mM)6 6 ±2 0.0001 87±10 0.23
PSN375963 (10mM)6 2 ±8 0.009 64±7 0.006
Abbreviations: GLP-1, glucagon-like peptide-1;KRBH, HEPES–Krebs–Ringer bicarbonate buffer; OEA, oleoylethanolamide.
MIN6c4 cells in 96-well plates were incubated in KRBH with 2.8mM glucose for 30min. Cells were subsequently made up to 2.8 and 16mM glucose with the
addition of the indicated concentrations of forskolin, GLP-1, OEA, PSN632408 and PSN375963. The cAMP levels were measured after 2h incubation by cAMP EIA
kit (Cayman Chemical Co.), then normalized to the protein concentration in each well. Three replicates were measured for every treatment and data are presented
as percentage of the level in 2.8mM glucose or in 16mM glucose (mean±s.e.mean). The cAMP level induced by 2.8mM glucose was 739±11.2pmolmg
 1
protein; the cAMP level induced by 16mM glucose was 963±7.9pmolmg
 1 protein. Data were analysed using Student’s t-test implemented in GraphPad Prism
4.0 (GraphPad Software Inc.).
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Glucagon-like peptide-1 (7–37), nitrendipine and diazoxide
were obtained from Sigma. OLPC, OEA, PSN375963 and
PSN632408 were obtained from Cayman Chemical
Company. MSD mouse insulin assay kit was obtained from
Meso Scale Diagnostic, LLC (Gaithersburg, MD, USA). The
calcium assay kit used in conjunction with FLIPR instru-
mentation (see below) was obtained from BD Biosciences.
Results
Effect of GPR119 agonists on insulin release in RINm5f and
RINm5f-GPR119 cell lines
To confirm the specificity of the endogenous and synthetic
GPR119 agonists, we utilized the rat RINm5f insulinoma
cell line. Although insulin secretion from RINm5f cells is not
glucose sensitive (Poitout et al., 1996; McClenaghan and Flatt,
1999), they do not express GPR119 endogenously (Supple-
mentary Figure 1) and provide a good background to assess
GPR119-specific signalling. We found that parental RINm5f
cells secreted insulin in response to GLP-1 (positive control)
and OLPC, but not to OEA (Figure 1a). In contrast, RINm5f
cells transfected with human GPR119 (RIN-119 cells) respon-
ded to OEA and had an increased response to OLPC
(Figure 1a), whereas the response to GLP-1 was unaffected.
Similarly, the two commercially available synthetic GPR119
agonists PSN275963 and PSN632408 did not increase insulin
secretion in the parental RINm5f but did increase insulin
secretion in RIN-119 cells (Figure 1b). These data suggest that
all four agonists do indeed signal through GPR119 in a
selective manner, although OLPC appears to act through
GPR119-independent mechanisms as well. For this reason,
OLPC was not used in subsequent studies.
Effect of GPR119 agonists on intracellular cAMP accumulation
GPR119 and GLP-1R are both Gs-coupled receptors and
activate intracellular adenylate cyclase. To compare agonist
activation of GPR119 with that of GLP-1R, intracellular
cAMP levels were explored in non-insulinoma cells (HEK293
and HEK293-GPR119) and insulinoma MIN6c4 cells. MIN6c4
cell line is a subclone of the commonly employed Min6 cell
line and was selected for glucose responsiveness and high
insulin production. This MIN6 subclone also shows a smaller
fold increase in GLP-1-stimulated insulin secretion (Professor
J Miyazaki, Osaka University Medical School, Osaka, Japan,
personal communication).
Forskolin, used as a positive control, generated a large
increase in cAMP in MIN6c4 cells under both high and low
glucose conditions. As expected, GLP-1 also induced a
significant increase in cAMP in both high and low glucose
conditions (Table 1). OEA induced a much lower increase in
cAMP in MIN6c4 cells compared with GLP-1 and only in
16mM glucose. PSN632408 was similar to OEA in this respect.
In contrast, PSN375963 suppressed cAMP production in
MIN6c4 cells in both high and low glucose (Table 1). In
contrast to MIN6c4 cells, both PSN632408 and PSN375963
increased cAMP in a concentration-dependent manner in
HEK293 cells overexpressed with GPR119 but not in un-
transfected HEK293 cells (Supplementary Figure 2). These data
suggest that PSN375963, although increasing cAMP through
GPR119 in HEK293-GPR119 cells, may suppress cAMP
through another mechanism, leading to the net decrease
observed in MIN6c4 cells.
Effect of endogenous GPR119 ligand OEA on insulin secretion and
calcium signalling
As mentioned above, insulin secretion by the RINm5f cell
line is not glucose sensitive. In addition, secreted insulin
levels in RINm5f are relatively low. Therefore, to investigate
the effects of GPR119 on glucose-dependent signalling, we
used MIN6c4 cells, which express GPR119 endogenously and
are glucose sensitive (Overton et al., 2006). The signalling
of endogenous ligands in 2.8mM (low) or 16mM (high)
glucose was examined first. Consistent with previous reports
(Drucker, 2006), the GLP-1-stimulated insulin secretion from
MIN6c4 cells was dependent on high extracellular glucose
(Figure 2a). Likewise, OEA also increased insulin secretion in
MIN6c4 in a glucose-dependent manner (Figure 2b).
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Figure 2 Glucagon-like peptide-1 (GLP-1) and oleoylethanolamide
(OEA) increase glucose-stimulated insulin secretion. MIN6c4 cells
were stimulated with the indicated concentrations of (a) GLP-1, (b)
OEA, in the presence of 2.8mM glucose or 16mM glucose. The
insulin levels were measured after 2h incubation. Three replicates
were measured for every treatment and data presented as ng
insulinml
 1 (mean±s.e.). *Po0.05; **Po0.01 using ANOVA-
Bonferroni, compared with insulin induced by glucose alone.
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increase in ½Ca
2þ ithrough a mechanism that involves cAMP
and the depolarization of the cell through the KATP channel
and subsequent opening of VDC channels (Light et al., 2002;
Tsuboi et al., 2003). GPR119 signalling also increases cAMP
(Soga et al., 2005; Overton et al., 2006) and induces GSIS;
however, the function of KATP and VDC channels in GPR119-
induced insulin secretion has not been demonstrated.
MIN6c4 cells were either maintained in 2.8mM glucose or
stimulated with 16mM glucose, then treated with the KATP
channel activator diazoxide (Ohno-Shosaku and Yamamoto,
1992; Chan et al., 2001) or the VDC channel inhibitor
nitrendipine (Ganesan et al., 1992; Zawalich and Zawalich,
1992), followed by the addition of OEA or GLP-1. The
resulting changes in ½Ca
2þ iand insulin secretion were then
measured.
As shown in Figure 3a, MIN6c4 exhibit a sustained increase
in ½Ca
2þ iafter stimulation with 16mM glucose. The addition
of 10nM GLP-1 further potentiates this increase in ½Ca
2þ i.
Treatment of the cells with either 5mM nitrendipine or
200mM diazoxide resulted in a rapid reduction of the glucose-
mediated calcium influx that GLP-1 was unable to rescue
(Figure 3a). GLP-1 potentiation of GSIS paralleled the effects
on calcium and was almost completely inhibited by either
nitrendipine or diazoxide (Figure 3b). OEA was similar to
GLP-1 in its effects on ½Ca
2þ iand insulin release (Figures 3c
and d). OEA at 10mM increased 16mM glucose-stimulated
½Ca
2þ iand was unable to overcome the inhibition by
nitrendipine or diazoxide (Figure 3c). Similarly, OEA increa-
sed GSIS and the addition of nitrendipine or diazoxide
dramatically reduced insulin secretion (Figure 3d).
Effect of PSN375963 and PSN632408 on insulin secretion and
calcium signalling in MIN6c4 cells
To compare the commercially available synthetic GPR119
agonists with OEA, concentration–response experiments,
using PSN375963 and PSN632408 in GSIS, were performed.
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Figure 3 Glucagon-like peptide-1 (GLP-1)- and oleoylethanolamide (OEA)-stimulated increases in insulin secretion are dependent on ATP-
sensitive K
þ (KATP) and voltage-dependent calcium channels. (a) MIN6c4 cells rested in HEPES–Krebs–Ringer bicarbonate buffer (KRBH) with
2.8mM glucose for 30min. Cells were then alternatively maintained in 2.8mM glucose and GLP-1 (10nM) added or brought to 16mM glucose
followed as indicated by GLP-1, nitrendipine (NTD, 5mM) and then GLP-1 or diazoxide (200mM) then GLP-1. Additions occurred at the times
indicated by the arrows and ½Ca
2þ i was continuously monitored. (b) MIN6c4 cells were rested in KRBH with 2.8mM glucose for 30min. Then
in the presence of 2.8mM or 16mM glucose (indicated), insulin secretion was stimulated with GLP-1 alone (10nM), GLP-1 plus nitrendipine
(NTD, 5mM) or GLP-1 plus diazoxide (200mM) were added. Nitrendipine and diazoxide were added 10min before GLP-1 and insulin release
was measured 2h later. Each treatment was performed in triplicate and data were presented as ng insulin per ml culture supernatant
(mean±s.e.mean). (c) is identical to (a) with the exception that OEA (10mM) is used in place of GLP-1. (d) is identical to B with the exception
that OEA (10mM) is used in place of GLP-1. *Po0.05; **Po0.01 using ANOVA-Bonferroni, compared with insulin induced by glucose alone.
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insulin secretion in the presence of either 2.8 or 16mM
glucose (Figure 4a). In contrast to PSN375963, PSN632408
increased insulin release in a glucose-dependent manner.
PSN632408 does not alter insulin secretion in the presence of
2.8mM glucose (Figure 4b). In the presence of 16mM glucose,
PSN632408 showed a bell-shaped concentration-dependent
effect on GSIS. At 1.1 and 3.3mM, PSN632408 increased
insulin by 25 and 39%, respectively, but at 10mM, it had no
significant effect (Figure 4b).
As before, we also examined calcium signalling with the
synthetic GPR119 agonists and the effect of diazoxide and
nitrendipine on calcium and insulin secretion in MIN6c4
cells. Unlike GLP-1 or OEA, PSN375963 induces an increase
in ½Ca
2þ iin MIN6c4 cells in the presence of 2.8mM glucose
(Figure 5a), but did not potentiate the increase in
½Ca
2þ iinduced by 16mM glucose (Figure 5b). In contrast,
PSN632408 showed the opposite effect and inhibited
½Ca
2þ iat both 2.8 and 16mM glucose (Figures 5c and d).
The function of the KATP and VDC channels in mediating
the effects of the synthetic agonists on insulin secretion was
also investigated. A concentration of 3.3mM was used for
both compounds, as PSN632408 was able to enhance GSIS at
this concentration, but did not inhibit ½Ca
2þ i. Glucose alone
(without KATP or VDC channel blockers) was used as a
control. As expected, diazoxide and nitrendipine both
inhibit the glucose-stimulated increases in ½Ca
2þ iand insulin
secretion (Figures 6a and b). As observed earlier, 3.3mM
PSN375963 increases ½Ca
2þ iin 2.8mM glucose but not in
16mM glucose (Figure 6c). Similarly, no increase
in GSIS was observed with PSN375963, and it did not
affect either nitrendipine or diazoxide inhibition of GSIS
(Figure 6d). PSN632408 at 3.3mM had no effect on ½Ca
2þ i
at either 2.8 or 16mM glucose (Figure 6e), whereas
PSN632408 did significantly increase GSIS, but it did not
alter diazoxide or nitrendipine inhibition of GSIS (Figure 6f).
Discussion
The ability of GPR119 activation to enhance GSIS has been
previously demonstrated (Chu et al., 2007, 2008); however,
the subsequent signals leading to insulin secretion have not
been reported. In this study, we have examined some of the
mechanisms underlying insulin release mediated by the
GPR119 ligand OEA and two recently reported synthetic
agonists, PSN375963 and PSN632408 (Overton et al., 2006).
We show here that GPR119 signalling by the endogenous
ligand is similar in many ways to that mediated by GLP-1R,
including modulation of ½Ca
2þ i, production of cAMP and
the dependence of insulin release on KATP and VDC
channels. The synthetic agonists PSN375963 and
PSN632408, however, have divergent effects on calcium
signalling, cAMP and insulin secretion in MIN6c4 cells,
which suggests that they may not be appropriate tools to
study GPR119-specific functions.
Among the GPR119 agonists examined in this study, OEA
appears the closest to GLP-1 in terms of its effects on GSIS
from MIN6c4 cells as well as in the associated signalling
events. In MIN6c4 insulinoma cells, OEA and GLP-1 both
increase insulin secretion in a glucose-dependent manner.
Consistent with this observation, both OEA and GLP-1
potentiate the increased ½Ca
2þ iobserved in response to
16mM glucose, whereas ½Ca
2þ iin 2.8mM glucose is unaf-
fected. In addition, they both increase cAMP content in
Min6c4 cells; however, OEA stimulates intracellular cAMP
production only in the presence of 16mM glucose, whereas
GLP-1 produces a more robust increase in cAMP and does
so in both low and high glucose. This may simply reflect
the relative potency of the ligands or, alternatively, the
characteristics of their respective receptors. More potent
and selective agonists for GPR119 should aid in determining
if this is a receptor- or ligand-based difference.
We also find that the GPR119-mediated increase of insulin
secretion from MIN6c4 cells, stimulated by the endogenous
ligand OEA requires KATP and VDC channels. Incubation of
MIN6c4 cells with diazoxide or nitrendipine not only
inhibits the increase in ½Ca
2þ iinduced by glucose but also
significantly blocks insulin secretion. The addition of
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Figure 4 PSN375963 and PSN632408 vary in their ability to
augment glucose-stimulated insulin secretion in MIN6c4 cells.
(a) MIN6c4 cells were stimulated with the indicated concentrations
of PSN375963 in the presence of 2.8mM glucose or 16mM glucose
(b) MIN6c4 cells were stimulated with the indicated concentrations
of PSN632408 in the presence of 2.8mM glucose or 16mM glucose.
For all experiments, the insulin levels were measured after 2h
incubation. Each treatment was performed in triplicate and data
were presented as ng insulin per ml of culture supernatant
(mean±s.e.mean). *Po0.05; using ANOVA-Bonferroni, compared
with insulin induced by glucose alone.
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overcome this inhibition. This is similar to the previously
reported findings that GLP-1 mediates an increase in
½Ca
2þ ithrough VDC channels (Light et al., 2002; Drucker,
2006).
In contrast to OEA, OLPC induces increased ½Ca
2þ iand
increased insulin secretion in MIN6c4 cells in both 2.8 and
16mM glucose (Supplemental Figure 3). The most likely
explanation for this is that OLPC signals in both a GPR119-
dependent and GPR119-independent manner. This hypoth-
esis is supported by the fact that OLPC increases insulin
secretion in RINm5f cells (which do not express GPR119) but
has a greater effect in RINm5f-GPR119 cells (Figure 1).
Although OEA appears to be more selective for GPR119 in
our studies, the data we have do not rule out the possibility
that OEA may also act independently of GPR119 in other
cells or tissues. Certainly, OEA is a known PPAR-a agonist
(Fu et al., 2003); however, OEA does not increase insulin
secretion from RINm5f unless they are transfected with
GPR119. It is also unlikely that a PPAR-a-mediated event
would be evident in the short time frame of the insulin
secretion assay.
Overall, our study shows that, to the extent that we have
examined the question, activation of GPR119 signalling by
the endogenous ligands is similar to that of GLP-1-stimu-
lated GLP-1R signalling. The endogenous ligand OEA bind-
ing to GPR119 leads to increased intracellular cAMP
accumulation (Table 1 and Overton et al., 2006) and, as we
have shown, enhances ½Ca
2þ iand insulin secretion in a
glucose-dependent manner. The effect of OEA on calcium
and insulin is also dependent on KATP and VDC channels.
Similar to the endogenous ligands, the synthetic GPR119
agonists PSN375963 and PSN632408 both increase
insulin secretion from RINm5f-GPR119 cells but not from
the parental RINm5f cell line. This suggests that these
compounds are indeed selective agonists for GPR119. This
conclusion is supported further by the fact that both of these
compounds increase intracellular cAMP in GPR119-trans-
fected HEK293 cells but not in untransfected control cells
(Supplementary Figure 2; Overton et al., 2006). Despite being
a GPR119 agonist, PSN375963 had no significant effect on
insulin secretion in MIN6c4 cells except at 10mM in 2.8mM
glucose (Figure 4a). Consistent with this observation, 10mM
PSN375963 increased ½Ca
2þ iin the presence of 2.8mM
02468 1 0
0
2000
4000
6000
8000
10000
12000
2.8 mM Glu
2.8 mM Glu+ 1.1 µM 963
2.8 mM Glu+ 3.3 µM 963
2.8 mM Glu+ 10 µM 963
Glu PSN375963
Time (min) Time (min)
F
l
u
o
r
e
s
c
e
n
c
e
 
c
h
a
n
g
e
 
(
c
o
u
n
t
s
)
F
l
u
o
r
e
s
c
e
n
c
e
 
c
h
a
n
g
e
 
(
c
o
u
n
t
s
)
02468 1 0
0
5000
10000
15000
20000
25000
30000
16 mM Glu
16 mM Glu+ 1.1 µM 963
16 mM Glu+ 3.3 µM 963
16 mM Glu+ 10 µM 963
Glu PSN375963
F
l
u
o
r
e
s
c
e
n
c
e
 
c
h
a
n
g
e
 
(
c
o
u
n
t
s
)
02468 1 0
–1000
0
1000
2000
3000
4000
5000
6000
2.8 mM Glu
2.8 mM Glu+ 1.1 µM 408
2.8 mM Glu+ 3.3 µM 408
2.8 mM Glu+ 10 µM 408
Glu PSN632408
Time (min) Time (min)
0 2 4 6 8 10
–1000
9000
19000
29000
16 mM Glu
16 mM Glu+ 1.1 µM 408
16 mM Glu+ 3.3 µM 408
16 mM Glu+ 10 µM 408
Glu PSN632408
F
l
u
o
r
e
s
c
e
n
c
e
 
c
h
a
n
g
e
 
(
c
o
u
n
t
s
)
Figure 5 PSN375963 and PSN632408 have opposite effects on [Ca
2þ]i in MIN6c4 cells. MIN6c4 cells were incubated in HEPES–Krebs–Ringer
bicarbonate buffer with 2.8mM glucose for 30min. Cells were subsequently maintained at 2.8mM glucose or brought to 16mM
glucose followed by the addition of the indicated concentrations of PSN375963 (a and b) or PSN632408 (c and d). ½Ca
2þ i was continuously
monitored by FLIPR.
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Figure 6 PSN375963 and PSN632408 effects are ATP-sensitive K
þ and voltage-dependent calcium channel dependent. (a and b)M I N 6 c 4c e l l s
were rested in HEPES–Krebs–Ringer bicarbonate buffer with 2.8mM glucose for 30min after which they were stimulated with 16mM glucose alone,
nitrendipine (5mM) followed by 16mM glucose, or diazoxide (200mM) followed by 16mM glucose as indicated. Channel blockers were pre-incubated
with cells for 10min before stimulation with glucose. Calcium signal was monitored by FLIPR (a) and insulin secretion was measured after 2h (b). Each
point was determined in triplicate. Data are presented as ng insulin per ml of culture supernatant (mean±s.e.mean). **Po0.01; using ANOVA-
Bonferroni, compared with insulin induced by glucose alone. (c and e)a r ei d e n t i c a lt o( a), with the exception that PSN375963 (3.3mM; c)o r
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16mM glucose alone, glucose plus PSN375963 (3.3mM; d) or glucose plus PSN632408 (3.3mM; f) was measured. Insulin secretion in response to
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after 2h and each point was determined in triplicate. *Po0.05, **Po0.01; using ANOVA-Bonferroni, compared with insulin induced by glucose alone.
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tions (Figure 5a). In 16mM glucose, the addition of
PSN375963 had no effect at any concentration (Figure 5b).
Given our previous observation that PSN375963 increased
cAMP in GPR119 transfected cells, we were surprised to see
that PSN375963 inhibited cAMP production in MIN6c4 cells.
The inhibition of cAMP occurred in both low and high
glucose conditions; however, the effect in high glucose was
significant only at 10mM PSN375963 (Table 1). This may be
the result of PSN375963 acting at another receptor in
MIN6c4 cells that is not present in HEK293 cells to activate
aG i-coupled pathway.
The other commercially available agonist, PSN632408, had
no effect on insulin secretion or ½Ca
2þ iin 2.8mM glucose,
but did increase MIN6c4 cell insulin secretion in the
presence of 16mM glucose. The effect on GSIS observed in
MIN6c4 cells showed a bell-shaped response, with a peak at
3.3mM PSN632408 (Figure 5b). PSN632408 also increased
cAMP in MIN6c4 cells, although similar to OEA, this effect
was observed only in the presence of 16mM glucose (Table 1).
The loss of enhanced GSIS at 10uM PSN632408 may be
the result of the inhibition of the glucose-stimulated increase
in ½Ca
2þ ithat is observed at higher concentrations of
PSN632408 (Figures 5c and d). This effect could act to
counter the enhancement of GSIS that might otherwise be
observed. As with the effects of PSN375963 on cAMP, it is not
clear if the effects of PSN632408 on calcium in the MIN6c4
cells is mediated through GPR119 or if it represents an off-
target effect of the compound. Given the relatively low
potency of these compounds (PSN632408 EC50¼1.9mM;
PSN375963 EC50¼13.9mM in HEK293-GPR119 cAMP), off-
target effects would not be unexpected. Attempts to address
this issue by inhibiting GPR119 expression in MIN6c4 cells
with RNAi were unsuccessful, and RINm5f cells are un-
responsive to glucose. Thus, at present, we lack a suitable
cell-based means for examining this question. The most
direct way to assess this might be to compare the response of
islets from GPR119 /  mice with those of wild-type
littermates. Arguing in favour of an off-target effect, OEA,
at 10mM did not inhibit ½Ca
2þ iand also increased both cAMP
and GSIS, despite having reported EC50 in cAMP assays
comparable with those of the synthetic ligands (Overton
et al., 2006). These findings are against the use of either
PSN375963 or PSN632408 as tools to examine GPR119-
specific function. Although AR231453 is not commercially
available, the data published by Chu et al. (2007) suggest that
it may be a more suitable tool.
Oleoylethanolamide as a ligand for GPR119 is of particular
interest, as it has been reported to be a peripherally acting
agent that suppresses food intake and reduces body weight
gain in rodent-feeding models (Fu et al., 2003; Nielsen et al.,
2004; Proulx et al., 2005). OEA has been shown to activate
PPAR-a (Fu et al., 2003; Guzman et al., 2004; Astarita et al.,
2006), and OEA inhibition of feeding requires the presence
of PPAR-a (Desvergne and Wahli, 1999; Fu et al., 2003). The
recent paper by Overton et al (2006) suggested that OEA’s
effects on feeding were mediated by GPR119. The basis for
this claim is that PSN632408 inhibited feeding in orally
dosed rats. Our data here suggest that caution should be used
in interpreting these results, as PSN632408 shows un-
expected activities at higher concentrations. Nonetheless, it
is still possible that stimulation of GPR119 might alter food
intake in rats. Rats have higher relative expression of GPR119
in the brain than mice or humans (JA Hedrick, unpublished
data). It cannot be ruled out that signalling through GPR119
in the rat brain might modulate feeding in these animals.
GPR119 is also expressed in the intestinal tract, and
stimulation of GPR119 in this tissue could in turn stimulate
the release of a secondary signal (for example, GLP-1 and
glucose-dependent insulinotropic polypeptide) that inhibits
feeding (Soga et al., 2005). Indeed, recent data from Chu et al.
(2008) suggest this is the case. In this regard, it is of interest
to note that we detect mRNA expression of GPR119 in the
GLUTag mouse intestinal L cell line as well as in the human
line NCI-H716 cells (JA Hedrick, unpublished data). Further
exploration into the potential function of GPR119 in
controlling food intake will be an interesting avenue of
future investigation.
Although this study improves our understanding of the
signalling mechanisms that underlie the physiological
functions of GPR119, our knowledge of GPR119 biology
remains incomplete and additional studies on the mecha-
nism of action of GPR119 are clearly warranted. We have
suggested here that GPR119 signalling shares some proper-
ties in common with GLP-1R signalling that leads us to
further questions. For example, it has been shown that
GLP-1R signalling can augment b cell mass in rodents via
activation of b cell proliferation and neogenesis (Li et al.,
2003). Does GPR119 also have a function in b cell survival
and apoptosis? If so, how similar are these effects to those of
GLP-1? Moreover, the GLP-1R ligands, GLP-1 and glucose-
dependent insulinotropic polypeptide exert actions well
beyond the b cell, and the function of these peptides in
peripheral organs such as adipose tissue, the brain and the
heart is receiving increasing attention. Similarly, how
important is GPR119 signalling in other tissues (for example,
intestine) and what effects might such signalling have? The
availability of high-potency, GPR119-selective synthetic
agonists in the future should assist in answering some of
these questions. However, it will be important to consider
the function of the endogenous ligands as we attempt to
comprehend better the function of GPR119 in regulating
insulin secretion.
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